NCT03432676 is a Phase 2 clinical trial of Epacadostat in ATM Gene Mutation, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT03432676?

NCT03432676 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03432676?

Interventions in NCT03432676: Epacadostat, Pembrolizumab.

What condition does NCT03432676 study?

NCT03432676 studies ATM Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Homologous Recombination Deficiency, Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8.

Is NCT03432676 still recruiting?

NCT03432676 is currently withdrawn. Last updated 30 May 2019.

Last reviewed 2019-05-30 · How we verify

NCT03432676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Withdrawn Phase 2 Last updated 30 May 2019

What this trial tests

Phase 2 trial testing Epacadostat in ATM Gene Mutation. Withdrawn.

Timeline

31 July 2019

Primary endpoint
30 April 2020

30 April 2021

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	31 July 2019
Primary completion	30 April 2020
Estimated completion	30 April 2021

Drugs / interventions tested

Epacadostat — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

ATM Gene Mutation — all drugs for ATM Gene Mutation →
Deleterious BRCA1 Gene Mutation — all drugs for Deleterious BRCA1 Gene Mutation →
Deleterious BRCA2 Gene Mutation — all drugs for Deleterious BRCA2 Gene Mutation →
Homologous Recombination Deficiency — all drugs for Homologous Recombination Deficiency →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with ATM Gene Mutation or Deleterious BRCA1 Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well epacadostat and pembrolizumab work in treating participants with pancreatic cancer that has spread to other places in the body. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving epacadostat and pembrolizumab may work better in treating participants with pancreatic cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K, Wu YH, Song Y, Yu B. · · 2021 · cited 276× · PMID 33883013 · DOI 10.1186/s13045-021-01080-8
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
Zhai L, Bell A, Ladomersky E, Lauing KL, et al · · 2020 · cited 168× · PMID 32612606 · DOI 10.3389/fimmu.2020.01185
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D, Ciecielski KJ, Ruess DA, Algül H. · · 2018 · cited 152× · PMID 30158932 · DOI 10.3389/fimmu.2018.01878
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.
Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. · · 2019 · cited 148× · PMID 30931508 · DOI 10.1186/s40169-019-0226-9
Trial watch: IDO inhibitors in cancer therapy.
Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, et al · · 2020 · cited 133× · PMID 32934882 · DOI 10.1080/2162402x.2020.1777625
Fighting in a wasteland: deleterious metabolites and antitumor immunity.
Watson MJ, Delgoffe GM. · · 2022 · cited 56× · PMID 35040434 · DOI 10.1172/jci148549
Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies.
Xu R, Yang J, Ren B, Wang H, et al · · 2020 · cited 52× · PMID 33117704 · DOI 10.3389/fonc.2020.572722
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities.
Young K, Hughes DJ, Cunningham D, Starling N. · · 2018 · cited 49× · PMID 30574212 · DOI 10.1177/1758835918816281

Verify or expand the search:

Other trials of Epacadostat

Trials testing the same drug.

NCT04231864 — Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasophary · Phase 2 · withdrawn
NCT03532295 — Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas · Phase 2 · completed
NCT03516708 — Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer · Phase 1, PHASE2 · recruiting
NCT03471286 — A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectab · Phase 1 · terminated
NCT03832673 — Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study · Phase 2 · withdrawn

Other recruiting trials for ATM Gene Mutation

Currently open trials in the same condition.

NCT06177171 — Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors · Phase 1 · recruiting
NCT05694715 — Combination Therapy in Cancers With Mutations in DNA Repair Genes · Phase 1 · recruiting
NCT05420064 — An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Inte · NA · recruiting
NCT03344965 — Olaparib In Metastatic Breast Cancer · Phase 2 · active not recruiting
NCT05097274 — The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03432676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 30 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03432676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing